Aquoral oral spray named to CareQuest’s 2026 oral health market map

CareQuest Innovation Partners named Aquoral Protective Oral Spray one of five dry mouth products in its 2026 Oral Health Innovation Market Map. The recognition could help broaden attention on a condition that affects patients who need longer-lasting relief and easier integration into dental workflows.

Why it matters: - CareQuest Innovation Partners put Aquoral Protective Oral Spray on its 2026 Oral Health Innovation Market Map as one of five products recognized for dry mouth. - The selection highlights a treatment category facing growing demand as dry mouth becomes more common and more disruptive for patients. - CareQuest’s report emphasized that oral health solutions need more than clinical value. They also need a practical path into care, fit within existing workflows and measurable value.

What happened: - K Pharmaceuticals announced that Aquoral Protective Oral Spray was recognized by CareQuest Innovation Partners as an innovative dry mouth product. - The recognition came in CareQuest Innovation Partners’ 2026 Oral Health Innovation Market Map. - K Pharmaceuticals is based in Phoenix, Arizona.

The details: - Aquoral uses a patented, lipid-based formula based on Oxidized Glycerol Triesters technology. - The spray coats the oral mucosa and forms a protective barrier. - K Pharmaceuticals says Aquoral can provide relief for up to 6 hours, including through eating and drinking. - The company positioned Aquoral against OTC aqueous-based products and prescription medications that can bring unwanted side effects. - Dry mouth has been linked in the release to polypharmacy, about 1,100 medications with dry mouth as a side effect, GLP-1 therapies, CPAP machines, sleep appliances, tobacco, alcohol and recreational drugs such as marijuana. - The company said dry mouth is often associated with older adults, Sjogren’s disease, head and neck cancer and radiation treatment, but is now often described as a “silent epidemic.”

Between the lines: - The CareQuest recognition gives Aquoral third-party validation in a crowded category. - The emphasis on workflow integration signals that market adoption may depend as much on clinic operations and access as on product performance. - K Pharmaceuticals is also trying to reduce friction for providers with training, implementation support, stocking and patient assistance tools. - CEO Bennett Blakeman said patients describe Aquoral as a “game changer” and said the goal is to improve oral health to improve overall health.

What’s next: - K Pharmaceuticals says it offers educational training, complimentary assets, ongoing support, an implementation protocol, a wholesale stocking program and a Patient Assistance Program. - The company directs readers to the 2026 Oral Health Innovation Market Map for the full report. - K Pharmaceuticals also points readers to Aquoral’s product site for more information.

The bottom line: - Aquoral’s inclusion in CareQuest’s market map could help the spray stand out as dry mouth treatment moves from a niche issue to a broader care and workflow challenge.